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We compared characteristics of community-associat-
ed methicillin-resistant Staphylococcus aureus (CA-MRSA)
skin and soft tissue infections (SSTIs) and CA-MRSA inva-
sive disease identified in Minnesota from 2000 through
2003. A total of 586 patients with SSTIs and 65 patients
with invasive disease were identified. Patients with invasive
disease were more likely to be smokers (p = 0.03), and
report a history of immunosuppressive therapy (p = 0.03),
emphysema (p = 0.011), or injection drug use (p = 0.020)
than were SSTI patients. Invasive disease isolates were
less likely to be susceptible to ciprofloxacin (p = 0.002) and
clindamycin (p = 0.001) and more likely to have healthcare-
associated pulsed-field gel electrophoresis subtypes than
SSTI isolates (p<0.001). Patients with invasive disease
may have had healthcare exposures that put them at risk of
acquiring healthcare-associated MRSA, and which were
not exclusion criteria in the CA-MRSA case definition.
Continued surveillance of MRSA is needed to better char-
acterize CA-MRSA infections.
M
ethicillin-resistant  Staphylococcus aureus (MRSA)
was first reported in 1961 and was recognized as a
nosocomial pathogen by the late 1960s (1,2). Known
MRSA risk factors include recent surgery or hospitaliza-
tion, residence in a long-term care facility, presence of a
percutaneous device or indwelling catheter, or recent dial-
ysis (3). 
In the 1980s, MRSA infections were reported in per-
sons who lacked traditional MRSA risk factors. These
infections appeared to be acquired in the community and
are now known as community-associated (CA) MRSA
infections. These infections have been reported worldwide
(4–18). Outbreaks have occurred in many settings and
among different populations (10,16,19–23).
Previous studies have demonstrated significant differ-
ences between MRSA isolates from persons with health-
care exposures and persons without these exposures in
both antimicrobial susceptibility results and pulsed-field
gel electrophoresis (PFGE) subtypes (5,7). Studies have
also demonstrated demographic differences between CA-
MRSA cases and healthcare-associated (HA) MRSA cases
regarding age, race, and income (5,7).
The most common clinical manifestations of CA-
MRSA are skin and soft tissue infections (SSTIs) such as
abscesses or cellulitis (5,7,9,24). Less commonly, CA-
MRSA can cause severe diseases such as necrotizing
pneumonia, osteomyelitis, and septicemia (6–9). Most
CA-MRSA infections resolve, but deaths from invasive
CA-MRSA disease have been reported (8).
Although invasive disease caused by CA-MRSA has
been described in the literature, no research has been pub-
lished that evaluates possible patient and isolate differ-
ences between CA-MRSA SSTIs and CA-MRSA invasive
disease. A subanalysis of CA-MRSA invasive disease
patients and SSTI patients and isolates was conducted by
using data collected from CA-MRSA prospective sentinel
surveillance in Minnesota from 2000 through 2003.
Methods
Facility Enrollment 
In 2000, 12 sentinel hospitals in Minnesota (6 in the 7-
county Minneapolis–St. Paul metropolitan area and 6 in
greater Minnesota) began reporting all cases of MRSAiso-
lated in their respective microbiology laboratories to the
Minnesota Department of Health (MDH). Characteristics
of these sentinel sites have been described elsewhere (7).
Case Enrollment 
Infection control practitioners from each hospital com-
pleted a case report form for patients with a positive
MRSA culture obtained during 2000–2003. Patient med-
ical records were reviewed to determine the type of
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diabetes, malignancy, chronic heart or lung conditions,
chronic skin conditions), or immunosuppressive therapy
(defined as long-term systemic steroid use, excluding top-
ical creams, steroids used only for short-course treatment,
and inhaled steroids used for asthma) and any history of
patient healthcare exposures as defined in the CA-MRSA
case definition. The hospital laboratories submitted CA-
MRSA isolates to MDH. 
All patients with cultures obtained during 2000–2002
who met the CA-MRSA case definition based on medical
record review were interviewed to confirm their classifica-
tion (patient culture dates 2000–2002) and to assess possi-
ble CA-MRSA risk factors (patient culture dates
2001–2002). Patients identified at 4 of the 12 sentinel sites
during 2003 who had no exclusionary healthcare expo-
sures noted on medical record review were contacted to
confirm CA-MRSA classification and conduct risk factor
interviews. In addition, a random sample of 2003 patients
from the remaining 8 sentinel sites were interviewed to
confirm CA-MRSA classification. Informed consent was
obtained from all patients before telephone interview. 
US Census data from 2000 were used to provide medi-
an income by zip code (25) as a proxy for case household
income. The University of Minnesota and MDH
Institutional Review Boards reviewed and approved the
study.
CA-MRSA Case Definition 
The Centers for Disease Control and Prevention (CDC)
Active Bacterial Core Surveillance Program defined a CA-
MRSA case as a patient with an MRSA infection and no
history of the following: surgery, hospitalization, or resi-
dence in a long-term care facility within the year before
infection, presence of a percutaneous device or indwelling
catheter, dialysis within the previous year, hospitalization
>48 h before MRSA culture, or previous MRSA infection
or colonization.
Patients were classified as confirmed CA-MRSA case-
patients if the medical record review and interview did not
show any of the above healthcare risk factors. Patients
were classified as probable CA-MRSA case-patients if the
medical record review did not show any healthcare risk
factors, but the interview was not completed (because of
patient refusal, inability to locate, or language barriers). 
Subanalysis Inclusion 
CA-MRSA patients identified from prospective sen-
tinel surveillance with culture dates in 2000 and 2003 were
included in this subanalysis if they had an SSTI (e.g.,
abscess, cellulitis, folliculitis, wound infection [nonsurgi-
cal]) or infection in a normally sterile site caused by CA-
MRSA. CDC’s Active Bacterial Core Surveillance
Program definition of sterile site infections was used to
define cases of invasive CA-MRSA disease. This defini-
tion defines a normally sterile site as a portion of the body
in a healthy state in which no microorganisms are found
and includes the following: blood, cerebrospinal fluid,
pleural fluid, peritoneal fluid, pericardial fluid, bone, joint
fluid, internal body site (lymph node, brain, heart, liver,
spleen, vitreous fluid, kidney, pancreas, or ovary), or other
normally sterile site. Although cases of necrotizing pneu-
monia caused by CA-MRSAhave been reported (26), CA-
MRSA specimens isolated only from sputum were not
included in our subanalysis because sputum was not
defined as a sterile site.
Isolate Characterization 
All MRSA isolates submitted to MDH were tested to
confirm Staphylococcus aureus identification by using a
tube coagulase test (27) (Difco Laboratories, Detroit, MI,
USA). Testing for antimicrobial susceptibility was per-
formed by using a broth microdilution panel (PML
Microbiologicals, Wilsonville, OR, USA) containing the
following 11 antimicrobial agents: ciprofloxacin, gentam-
icin, trimethoprim/sulfamethoxazole, clindamycin, tetra-
cycline, erythromycin, rifampin, linezolid, mupirocin,
vancomycin, and oxacillin. Clinical and Laboratory
Standards Institute (CLSI, formerly National Committee
for Clinical Laboratory Standards) breakpoints were used
to determine levels of resistance for all antimicrobial
agents except mupirocin, for which no CLSI breakpoints
exist (28). A standard of <4 µg/mL was used as a break-
point for susceptibility to mupirocin (29). 
Molecular Characterization 
Molecular subtyping of MRSA isolates was performed
by PFGE and digestion with the restriction endonuclease
SmaI (30). Patterns were evaluated both visually and with
BioNumerics software (Applied Maths, Kortrijk, Belgium)
by using the dice coefficient. Indistinguishable patterns
must visually appear identical, and the DNA patterns must
differ by <1.5% with respect to molecular weight. MRSA
isolates were considered part of a CA-MRSA pulsed-field
type (PFT) if they were >80% similar to the USA300 or
USA400 reference strains based on Dice coefficients.
MRSAisolates were considered part of an HA-MRSAPFT
if they were ≥80% similar to USA100, USA200, or
USA500–800 reference strains (30).
Statistical Analysis 
The Yates continuity corrected chi-square test was used
to test for trends with EpiInfo version 6.2 (CDC, Atlanta,
GA, USA), and univariate analysis of the data was per-
formed with EpiInfo 2000 (CDC). Multivariate logistic
regression was used to evaluate the association of the type
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microbiologic and molecular features of the MRSA iso-
lates. Demographic characteristics associated with the
type of infection in the univariate analysis were controlled
for in the multivariate analysis model. An α<0.05 signifi-
cance level was required for predictors to remain in the
model. Multivariate analysis was accomplished by using
SAS version 8.0 for Windows (SAS Institute, Cary, NC,
USA).
Results
A total of 738 CA-MRSA infections were identified
from January 1, 2000, to December 31, 2003. SSTIs
accounted for 79% (586/738) of all infections reported,
and invasive disease accounted for 9% (65/738) of all CA-
MRSA infections reported. The proportion of CA-MRSA
infections that were invasive did not differ significantly
over the study period. The most common site of invasive
disease was the bloodstream (50%), followed by joint or
bone (32%). Clinical information was available for 511
(87%) of 586 SSTI patients. The most common clinical
conditions reported for SSTIs were abscesses (49%) and
cellulitis (33%) (Table 1).
Case Demographics 
Invasive disease patients were more likely to be male
than SSTI patients (66% vs. 51%, odds ratio [OR] 1.89,
95% confidence interval [CI] 1.10–3.24). No difference in
median age was found between the 2 groups. Race infor-
mation was available for 54 (83%) of 65 invasive disease
patients and 477 (81%) of 586 SSTI patients. No differ-
ence was shown between the 2 groups when race was ana-
lyzed in terms of white and nonwhite race categories
(Table 2).
Patient hospitalization status was available for all of the
invasive disease CA-MRSApatients and 562 (96%) of 586
SSTI patients. As expected, invasive disease patients were
more likely to be hospitalized for their infection than were
SSTI patients (OR 6.89, 95% CI 3.81–12.4). Results
remained significant after controlling for age and sex
(p<0.001). No differences were observed between median
income of CA-MRSA invasive disease patients and SSTI
patients (Table 2).
History of underlying medical conditions was obtained
for 58 (89%) of 65 invasive disease patients and 515 (88%)
of 586 SSTI patients. Invasive disease patients were more
likely to report a history of underlying illness than were
SSTI patients (OR 2.08, 95% CI 1.05–4.20). Invasive dis-
ease CA-MRSA patients were more likely to have a histo-
ry of immunosuppressive therapy (OR 9.31, 95% CI
1.87–47.2), solid organ malignancy (OR 9.16, 95% CI
1.27–66.3), or emphysema/chronic obstructive pulmonary
disease (COPD) (OR 13.9, 95% CI 2.29–85.5) than SSTI
patients. Invasive disease CA-MRSA patients were also
more likely to be current smokers (OR 2.18, 95% CI
1.09–4.67) or injection drug users (OR 5.56, 95% CI
1.29–23.9) than SSTI patients. History of underlying ill-
ness (p = 0.007), immunosuppressive therapy (p = 0.003),
emphysema/COPD (p = 0.012), current smoking (p =
0.028), and injection drug use (p = 0.021) remained signif-
icant in a multivariate model that controlled for age and
sex (Table 2). 
Isolate Characteristics 
We received isolates from 60 (92%) of 65 invasive dis-
ease patients and 525 (90%) of 586 SSTI patients. Tests for
antimicrobial drug susceptibility were completed on 57
(95%) of 60 invasive disease isolates and 517 (98%) of
525 SSTI isolates. All isolates were susceptible to linezol-
id and vancomycin. Compared with SSTI isolates, those
from invasive infections were less likely to be susceptible
to ciprofloxacin (OR 2.79, 95% CI 1.54–5.04) and clin-
damycin (OR 3.34, 95% CI 1.67–6.69). When
ciprofloxacin and clindamycin susceptibilities were ana-
lyzed in a model that controlled for sex and age, the results
remained significant (p = 0.002 and p = 0.001, respective-
ly) (Table 3). 
Initial antimicrobial therapy information was docu-
mented for 41 (63%) of 65 patients with invasive disease
whose isolates were available and for 415 (71%) of 586
patients with SSTI whose isolates were available. For 27
(66%) of 41 invasive disease patients and 333 (80%) of
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scribed was of a class to which the organism was resistant.
Invasive disease patients were more likely to be empirical-
ly treated with an antimicrobial drug to which their MRSA
isolate was susceptible than were SSTI patients (OR 2.10,
95% CI 1.05–4.20). Results remained significant after con-
trolling for age and sex (p = 0.015).
All available isolates received were characterized by
PFGE. Fifty-three (88%) of 60 invasive disease isolates
and 501 (95%) of 525 SSTI isolates had PFGE subtypes
that could be categorized into PFTs that have been associ-
ated with HA-MRSA disease (USA100, USA200,
USA500–800) or CA-MRSA (USA300 and USA400)
(30). Compared with PFGE subtypes from SSTI isolates,
PFGE subtypes from invasive disease isolates were more
likely to be associated with HA-MRSA PFTs (OR 3.63,
95% CI 2.03–6.50). This result remained significant after
controlling for age and sex (p<0.001) (Table 4). When
invasive disease and SSTI case isolate susceptibility to
ciprofloxacin and clindamycin were analyzed in a multi-
variate model that controlled for CA or HA-MRSA PFT
and sex, no difference in susceptibility patterns was found
between the 2 groups (Table 3).
Confirmed CA-MRSA Analysis 
Three hundred two (52%) of 586 SSTI patients and 36
(55%) of 65 invasive disease patients were confirmed
(through patient interview and medical record review, as
opposed to medical record review alone) to meet the CA-
MRSAcase definition. Confirmed CA-MRSApatients and
isolates underwent the previously described analysis
regarding differences in underlying conditions and isolate
antimicrobial susceptibility. Underlying condition infor-
mation was available for 30 (83%) of 36 invasive disease
patients and 273 (90%) of 302 SSTI patients. Confirmed
invasive disease CA-MRSApatients were more likely than
confirmed SSTI patients to report a history of underlying
illness (OR 2.36, 95% CI 1.09–5.10), history of immuno-
suppressive therapy (OR 10.0, 95% CI 1.92–52.0), solid
organ malignancy (OR 19.4, 95% CI 1.71–221), or to be a
current smoker (OR 3.06, 95% CI 1.25–7.50). Hospital-
ization information was available for all invasive disease
patients and 299 (99%) of 302 SSTI patients. Confirmed
invasive disease patients were more likely to be hospital-
ized for their infection than were confirmed SSTI patients
(OR 5.94, 95% CI 2.75–12.8). Isolates were available for
30 (83%) of 36 invasive disease patients and 265 (88%) of
302 SSTI patients. Confirmed CA-MRSAinvasive disease
isolates were less likely to be susceptible to ciprofloxacin
(OR 5.02, 95% CI 2.11–12.0) and clindamycin (OR 5.75,
95% CI 2.58–12.8). Twenty-eight (93%) of 30 invasive
disease isolates and 257 (85%) of 302 SSTI isolates could
be categorized into PFTs that have been associated with
HA-MRSA or CA-MRSA. Invasive disease isolates were
more likely to have HA-MRSA PFTs than were SSTI iso-
lates (OR 4.24, 95% CI 1.90–9.43). When invasive disease
Methicillin-resistant Staphylococcus aureus, Minnesota
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damycin were analyzed in a multivariate model that con-
trolled for CA- or HA-MRSA PFT and sex, invasive
disease isolates were still more likely to be resistant to
ciprofloxacin than were SSTI isolates (p = 0.04). 
Discussion
This report compares CA-MRSA invasive disease
patients and their isolates with those of SSTI patients.
Invasive disease patients were more likely to be male and
more likely to have a history of underlying conditions
(immunosuppressive therapy, emphysema/COPD, injec-
tion drug use, and smoking) than were SSTI patients.
Invasive disease isolates were similar to HA-MRSA iso-
lates in that they were resistant to additional antimicrobial
drugs (clindamycin and ciprofloxacin) and were more like-
ly to belong to a PFT usually associated with HA-MRSA
(7). These similarities suggest that invasive CA-MRSA
patients may have had healthcare exposures that put them
at risk of acquiring HA-MRSA, even though they are clas-
sified as CA-MRSA by the current CDC case definition.
The results of the ciprofloxacin and clindamycin multi-
variate analysis, including PFT association with both con-
firmed and probable CA- or HA-MRSA, showed no
difference in susceptibility patterns between invasive dis-
ease and SSTI isolates. This suggests that the initial differ-
ences in susceptibility were not due to more resistant
CA-MRSAstrains causing invasive disease, but rather that
more of the invasive disease isolates classified as CA-
MRSA were actually HA-MRSA strains, which are typi-
cally resistant to more antimicrobial agents. However,
when this same analysis was conducted by using con-
firmed CA-MRSA cases only, invasive disease isolates
were still more likely to be resistant to ciprofloxacin. More
research is needed to determine whether invasive disease
CA-MRSA isolates are more resistant to antimicrobial
drugs than CA-MRSA isolates that cause SSTI.
Invasive disease patient characteristics identified in this
analysis were similar to results from other studies, which
found that CA invasive disease patients had underlying
conditions such as diabetes, smoking, and cardiovascular
disease (31,32). The underlying conditions identified in the
S. aureus and MRSA patients in these studies do not dis-
qualify them from meeting the current CDC CA-MRSA
case definition, yet these conditions may have put them at
risk of acquiring HA-MRSA. 
One possible explanation for some of the results of this
analysis could be the likelihood that invasive disease
patients had more healthcare exposures than did SSTI
patients. This hypothesis is supported by the fact that inva-
sive disease patients reported serious underlying illnesses
that would imply a history of extensive healthcare con-
tacts. During these healthcare contacts, invasive disease
patients may have been colonized by HA-MRSAstrains. A
recent study found that in 50% of patients nasally colo-
nized with MRSAsubsequent infection developed over the
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mine the colonization status of our patients for this analy-
sis, patients have been found colonized with MRSAfor up
to 40 months (34). 
This study has several limitations. Although the hospi-
tal laboratories were selected to reflect state population
demographics, the study was not population based.
Therefore, generalizing the findings to entire state popula-
tion is not possible. Also, some HA-MRSA patients may
have been misclassified as CA-MRSA patients because of
incomplete ascertainment of HA risk factors. However,
since no major differences were found in results when
analysis was restricted to confirmed CA-MRSA patients,
misclassification bias as a result of incomplete ascertain-
ment of HA risk factors that are exclusion criteria for the
current CA-MRSA case definition is unlikely to be a large
factor. In addition, the sample size, particularly of invasive
disease cases, limited the ability to detect small statistical
differences between the 2 groups. Finally, complete data
on all cases were not available for all factors analyzed in
this report. These missing data could have biased the
results of this analysis.
Underlying conditions or healthcare exposures not cur-
rently included as exclusion criteria in the CA-MRSAcase
definition may put patients at risk of HA-MRSA coloniza-
tion and infection. In addition, persons with underlying
conditions may also be at greater risk of invasive disease
caused by MRSA. Clinicians should be aware of possible
serious MRSA infections in persons without previously
recognized HA-MRSA risk factors. Continued surveil-
lance of CA-MRSA is needed to further define the epi-
demiology of invasive disease and SSTI and to develop
recommendations for the prevention and control of this
emerging public health threat. 
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